Key Highlights

• PYC Therapeutics (ASX:PYC) closed at A$1.93, gaining 4.32% on 05 November 2026, outpacing the ASX 200 Health Care index's 3.64% advance

• PYC-003 progressed to dosing at 2.4 mg/kg in the Phase 1b Multiple Ascending Dose study for polycystic kidney disease

• All four Drug Development programs advanced during Q3 CY2026, with a fourth candidate expected to enter human trials in 2027

Shares of PYC Therapeutics Ltd (ASX:PYC) closed at A$1.93 on 05 November 2026, gaining 4.32% during the session. The S&P/ASX 200 (XJO) gained 2.61%, rising 230.60 points to 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, adding 1,240.30 points to reach 35,329.10. Overnight Wall Street gains, following the Democrats' decisive victory in the U.S. midterm elections, supported a broad-based rally across global markets. PYC Therapeutics is a Perth and San Diego-based biotechnology company developing precision RNA medicines for patients with genetic diseases and limited treatment options.

Polycystic Kidney Disease Program Advances Dosing

On 29 October 2026, PYC provided its Q3 2026 Shareholder update, reporting that its lead PKD program had progressed to dosing at 2.4 mg/kg of PYC-003 in the Phase 1b Part C Multiple Ascending Dose (MAD) study. This followed the Safety Review Committee's evaluation of Single Ascending Dose study data and results from the 1.2 mg/kg patient cohort. PYC also initiated dosing in an Open Label Extension study (Part D), enabling eligible participants to receive PYC-003 continuously for up to 24 months, mirroring the anticipated duration of the registrational trial. Clinical safety data from completed single-dose cohorts were presented at the Australian and New Zealand Society of Nephrology conference and the American Society of Nephrology conference.

Phelan-McDermid Syndrome and Optic Atrophy Programs

PYC's Phelan-McDermid Syndrome (PMS) program progressed into Investigational New Drug enabling studies during Q3. Pre-clinical data supporting the disease-modifying potential of PYC-002 were presented at the PMS Foundation family conference. In the Autosomal Dominant Optic Atrophy (ADOA) program, safety and tolerability and efficacy data from the ongoing Phase 1/2 studies of PYC-001 were presented at the Neuro-Ophthalmology Society of Australia conference. Safety and tolerability and efficacy data from the Phase 1/2 studies of VP-001 in participants with Retinitis Pigmentosa type 11 (RP11) were presented at the Euretina congress.

Pipeline Breadth and Fourth Candidate

PYC's pipeline now encompasses four drug development programs targeting diseases caused by insufficient gene expression. The company disclosed that a fourth investigational drug candidate is expected to enter human trials in 2027, subject to regulatory alignment. PYC's RNA therapeutic approach is designed to precisely increase gene expression while limiting the risk of over-expressing the target gene.

About PYC Therapeutics – Business Overview

PYC Therapeutics is a clinical-stage biotechnology company developing precision RNA medicines for genetic diseases with unmet medical need. The company operates from Perth, Australia, and San Diego, California. Its pipeline includes PYC-003 for polycystic kidney disease, PYC-002 for Phelan-McDermid Syndrome, PYC-001 for autosomal dominant optic atrophy, and VP-001 for retinitis pigmentosa type 11. The company's technology platform focuses on diseases caused by haploinsufficiency, where RNA therapeutics can address the underlying genetic cause.

Sector Context

The ASX healthcare sector gained 3.64% on 05 November 2026. Clinical-stage biotechs participated in the broader market rally, supported by the risk-on environment. PYC's 4.32% gain was modestly above the healthcare benchmark, consistent with the positive sentiment across the sector.

Risks

PYC faces the typical risks of a pre-revenue clinical-stage biotech, including the uncertainty of clinical trial outcomes across its four programs. The company is dependent on its cash reserves and potential future Capital raises to fund ongoing trials and operations. Regulatory hurdles, particularly for the novel RNA therapeutic modality, add complexity. Competition from larger pharmaceutical companies developing alternative treatments for the same indications is an ongoing consideration, and the timeline for any potential Revenue generation from approved products remains extended.

Catalysts on Watch

Key catalysts include the readout from higher dose cohorts in the PYC-003 PKD trial, data from the Open Label Extension study, and IND submission for the fourth drug candidate expected in 2027. Conference presentations throughout CY2027 may provide additional clinical data across all four programs. Any regulatory interactions or Partnership discussions could also represent material developments.

What It All Means

PYC Therapeutics' Q3 2026 update demonstrated parallel advancement across its four-program precision medicine pipeline. The PKD program's dose escalation to 2.4 mg/kg and the initiation of the Open Label Extension study represent the most advanced clinical milestones, while earlier-stage programs in PMS, ADOA, and RP11 continue to generate clinical data.